The FDA has granted Otsuka Holdings and H. Lundbeck approval for Abilify Maintena, a once-a-month injection for patients with schizophrenia. The drug was associated with significant delays in relapse compared with placebo, the company said.
Once-monthly Abilify gains FDA nod
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|